Donald K. Carter

TL;DR: Consistent with previous trials, the MRKAd5 HIV-1 gag/pol/nef vaccine was highly immunogenic for inducing HIV-specific CD8+ T cells and suggest that future candidate vaccines have to elicit responses that either exceed in magnitude or differ in breadth or function from those recorded in this trial.

TL;DR: The MRKAd5 HIV- 1 vaccine did not prevent HIV-1 infection or lower viral-load setpoint; however, stopping the trial early probably compromised the ability to draw conclusions.

TL;DR: This study illustrates the power of combined DNA approaches to generate impressive immune responses in humans by using electroporation after PV administration to provide immunogenicity superior to that observed in the trial without Electroporation, despite fewer vaccinations.

TL;DR: This work has identified and compared adenovirus-specific and HIV-specific T cell responses in subjects participating in two HIV-1 vaccine trials using a vaccine vectored by adenvirus serotype 5 (Ad5), and provides what it believes to be a new understanding of how preexisting viral immunity may impact the efficacy of vaccines.

TL;DR: PBMC from 12 HIV-infected and 12 uninfected donors showed that Ln/LN conferred higher viability and recovery than LN/DI or 70/DI 3, 6, 9 or 12, and ELISPOT values significantly decreased with the duration of storage at -70°C both in HIV- Infected and unin infected donors.